Cargando…

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for solid tumors. However, even in cancers generally considered ICI-sensitive, responses can vary significantly. Thus, there is an ever-increasing interest in identifying novel means of improving therapeutic responses, both...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metropulos, Anastasia E., Munshi, Hidayatullah G., Principe, Daniel R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706619/ https://www.ncbi.nlm.nih.gov/pubmed/36455409 http://dx.doi.org/10.1016/j.ebiom.2022.104380

Ejemplares similares

Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
por: Principe, Daniel R., et al.
Publicado: (2021)

Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8(+) T cell antitumor immunity
por: Pham, Thao N.D., et al.
Publicado: (2022)

BET inhibition rescues ciliogenesis and ameliorates pancreatitis-driven phenotypic changes in mice with Par3 loss
por: Shields, Mario A., et al.
Publicado: (2023)

Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin
por: Shields, Mario A., et al.
Publicado: (2022)

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
por: Sow, Heng Sheng, et al.
Publicado: (2019)

Successful clinical translation of preclinical combinations of radiation and immunotherapy
por: Formenti, Silvia C., et al.
Publicado: (2013)

Transforming of the Tumor Microenvironment: Implications for TGF-β Inhibition in the Context of Immune-Checkpoint Therapy
por: Löffek, Stefanie
Publicado: (2018)

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
por: Principe, Nicola, et al.
Publicado: (2022)

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
por: Schaer, David, et al.
Publicado: (2015)

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021)

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
por: Bai, Xianguang, et al.
Publicado: (2019)

Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation
por: Principe, Daniel R., et al.
Publicado: (2016)

XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
por: Ni, Ying, et al.
Publicado: (2021)

Intestinal adenocarcinoma originating from an undiagnosed Meckel’s diverticulum
por: Principe, Daniel R, et al.
Publicado: (2022)

Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
por: Sokolowska, Olga, et al.
Publicado: (2022)

Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
por: Zhang, Mengxian, et al.
Publicado: (2012)

Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
por: Kidman, Joel, et al.
Publicado: (2020)

Alveolar soft part sarcoma mimics prostate cancer metastasis
por: Principe, Daniel R, et al.
Publicado: (2019)

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
por: Simonsen, Lotte, et al.
Publicado: (2022)

Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials
por: Jiang, Minhan, et al.
Publicado: (2023)

Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models
por: Lu, Xinjun, et al.
Publicado: (2023)

Preclinical research in Rett syndrome: setting the foundation for translational success
por: Katz, David M., et al.
Publicado: (2012)

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC
por: Sulaiman, Andrew, et al.
Publicado: (2021)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

TGFβ Signaling in the Pancreatic Tumor Microenvironment
por: Principe, Daniel R., et al.
Publicado: (2021)

Controlling TIME: How MNK Kinases Function to Shape Tumor Immunity
por: Pham, Thao N.D., et al.
Publicado: (2020)

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
por: Ge, Zhouhong, et al.
Publicado: (2021)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
por: Ott, Patrick A., et al.
Publicado: (2015)

Richard Hynes, Erkki Ruoslahti, and Timothy Springer receive Lasker prize for pioneering work on integrins
por: Munshi, Hidayatullah G.
Publicado: (2022)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
por: Peyraud, Florent, et al.
Publicado: (2020)

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function
por: Principe, D R, et al.
Publicado: (2017)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
por: Hwang, June Kyu, et al.
Publicado: (2020)

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2022)

RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade
por: Ganesh, Shanthi, et al.
Publicado: (2018)

The Post-translational Modifications of Smurf2 in TGF-β Signaling
por: Bai, Yangjinming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4cli8m45n45mfdc3qs8vdmgf51